FTO/m6A/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment?

Gut. 2024 Dec 10;74(1):5-6. doi: 10.1136/gutjnl-2024-332934.

Authors

Bernd Heinrich¹, Francisco Javier Cubero^{2

3}

Affiliations

¹ Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany [email protected].
² Immunology, Ophthalmology and ENT, Complutense University of Madrid Faculty of Medicine, Madrid, Spain.
³ Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

PMID: 39089861
DOI: 10.1136/gutjnl-2024-332934

No abstract available

Keywords: HEPATOCELLULAR CARCINOMA; IMMUNE RESPONSE.